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AHHS 389 Syllabus 
Spring Semester 2014 
Recent Advances in Clinical Medicine: Neurological Health 
 
Class meets every Thursday at 12:10 p.m. in Skaggs Building 169 
Course Coordinator: Kim Madson, PharmD, SB 318, 243-6635, pharmacy.ce@umontana.edu 
                         
January 30 
 
 
 
 
Methamphetamine as a Neuroprotective Agent to 
Treat Traumatic Brain Injury 
Dave Poulsen, PhD 
Research Professor, Biomedical & Pharmaceutical 
Sciences 
University of Montana 
 March 27 
 
 
         
         
Neurological Complications of HIV Infection 
Gary Meyers, PharmD 
Northwest AIDS Education and Training Center 
Billings, Montana 
 
February 6 
 
 
Seizures after Traumatic Brain Injury 
Tom Swanson, MD  
Montana Neurology 
Missoula, Montana 
 April 3 
 
 
 
   
 
February 13 
           
 
          
Nutrition and the Brain:  Evidence and Potential 
Mechanisms 
Sarah Miller, PharmD, BCNSP 
Professor, Pharmacy Practice 
University of Montana 
 April 10 
 
 
        
From Benchside to Bedside:  Understanding and 
Treating Parkinson’s Disease 
Fernando Cardoza, PhD 
Associate Professor, Biomedical & Pharmaceutical 
Sciences 
University of Montana 
February 20 
 
 
         
            
Glial Brain Tumors 
Richard Bridges, PhD  
Professor and Chair, Biomedical & Pharmaceutical 
Sciences 
University of Montana 
 April 17 
 
 
         
       
Traumatic Brain Injury Medicine:  A Brief Overview 
with an Emphasis on Pharmacological Management 
Bill Rosen, MD 
Physical medicine & rehabilitation specialist 
Missoula, Montana 
 
February 27 
 
 
          
         
Multiple Sclerosis: Barriers to Medication 
Adherence 
Doug Allington, PharmD, BCPS 
Associate Professor, Pharmacy Practice 
University of Montana 
 
 April 24 
 
 
         
      
Medication Challenges for Brain Injury Patients 
Lois McElravy 
Brain Injury Thriver 
Missoula, MT 
 
March 6 
 
          
        
 
Alzheimer’s Disease and You 
John Schaefer, DO 
Montana Neurological Specialists 
Missoula, Montana  
 
 May 1 
 
       
      
       
Oxidative Stress and its Role in Underlying Ischemic-
Reperfusion-Induced Delayed Neuronal Death 
Darrell Jackson, PhD 
Associate Professor, Biomedical & Pharmaceutical 
Sciences 
University of Montana 
 
March 13          
 
 
 
          
Natural Products and Ayurvedic Therapies for 
Neurological Disorders 
Diana Lurie, PhD 
Professor, Biomedical & Pharmaceutical Sciences 
University of Montana 
 
 May 8 
   
 
 
       
The Basic Neurological Exam: Why We Do What We 
Do? 
Ben Grass, MD 
Medical Resident; Family Medicine Residency of 
Western Montana 
 
Ned Vasquez, MD 
Director; Family Medicine Residency of Western 
Montana  
March 20 
 
           
          
          
Menstrual Migraines:  Potential Causes and 
Modalities 
Donna Beall, PharmD, BCPS 
Professor, Pharmacy Practice 
University of Montana  
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Academic participants: There will be fourteen class meetings of AHHS 389 during the Spring Semester, 2014.  To receive academic 
credit for the course, you must attend 12 of the 14 classes.  To verify your attendance, you must sign in on the roster that will be 
circulated at each class meeting.  If you fail to attend twelve complete sessions, you will receive a ‘NP’ in the course.  If you find that 
you must miss more than one session with valid reason, please see the Course Coordinator ASAP.  Attendance will be logged in Moodle 
weekly.  Please pay close attention to your attendance record and report any discrepancies to the instructor. All students must practice 
academic honesty. Academic misconduct is subject to an academic penalty by the course instructor and/or a disciplinary sanction by the 
University.  All students need to be familiar with the Student Conduct Code. The Code is available for review online at 
http://life.umt.edu/vpsa/student_conduct.php. 
 
Knowledge Assessment: Self-tests will be distributed at the conclusion of the program. Each pre/post learning assessment is 
for participant use only and will not be graded.  
 
Evaluations: Speaker evaluations will be distributed along with knowledge assessments as described above. Student feedback 
on the quality and effectiveness of selected speakers, topics, teaching methodologies, and the overall course is invaluable to 
the ongoing success of this academic and continuing professional education program. Completed speaker evaluations should 
be returned to the Course Coordinator at the end of each class.  Course evaluations will be distributed and collected at the 
end of the final lecture on May 8
th
.   
 
Goal: This lecture series for students, pharmacists, and health professionals will update participants on recent advances in 
neurological health. 
 
Learning Objectives: At the conclusion of each of the individual lectures, the participant will be able to: 
 
1/30/14 – Methamphetamine as a Neuroprotective Agent to Treat Traumatic Brain Injury 
 Explain the general consequences of brain injury. 
 Explain preclinical approaches to the development of new drugs to treat Traumatic Brain Injury (TBI). 
 Define important mechanisms of action for effective neuroprotective agents. 
 
2/6/14 – Seizures After Traumatic Brain Injury 
 TBA 
 
2/13/14 – Nutrition and the Brain:  Evidence and Potential Mechanisms 
 Summarize evidence as to whether or not antioxidants, B vitamins, omega 3 fatty acids, gingko, and medical foods can 
slow progressive of cognitive impairment. 
 Classify common so-called “brain foods” as to how they might be beneficial to cognitive function. 
 
2/20/14 – Glial Brain Tumors 
  TBA 
 
2/27/14 – Multiple Sclerosis:  Barriers to Medication Adherence 
 Differentiate between definitions of compliance and adherence. 
 If given a case, analyze which medication adherence barriers are present. 
 If given a case, formulate a strategy to eliminate or mitigate common physician or patient-based medication adherence 
barriers. 
 
3/6/14 – Alzheimer’s Disease and You 
 Identify current pharmacologic treatments for Alzheimer Disease and describe how they work. 
 Recognize the risk factors for Alzheimer Disease. 
 Describe which proteins are thought to play a role in the development of Alzheimer Disease. 
 Name the genes known to play a role in Alzheimer Disease. 
 
3/13/14 – Natural Products and Ayurvedic Therapies for Neurological Disorders 
 Explain the definition of CAM (Complementary and Alternative Medicine). 
 Identify several herbs and natural products that have been used traditionally in Ayurvedic medicine to treat neurological 
diseases. 
 Describe the scientific literature that either validates or invalidates these natural products. 
 Define the role that neuroinflammation plays in neurological disease and how CAM therapies impact the CNS 
inflammatory response. 
 Describe the various Ayurvedic body therapies that are used to treat neurological dysfunction. 
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3/20/14 – Menstrual Migraines:  Potential Causes and Modalities 
 Differentiate between the characteristics of a common migraine and menstrual migraine. 
 Describe the non-pharmacologic and pharmacologic treatment modalities used to manage menstrual migraines. 
 
3/27/14 – Neurological Complications of HIV Infection 
 Identify common neurological manifestations of HIV infection. 
 Describe specific symptoms or clinical markers of neurological decline in HIV+ patients. 
 State the specific cells affected by HIV infection. 
 Distinguish the difference between direct and indirect nervous systems effects of HIV infection. 
 Define specific treatment options for opportunistic infections that involve the brain. 
 
4/10/14 – From Benchside to Bedside:  Understanding and Treating Parkinson’s Disease (PD) 
 Describe the clinical, neurochemical, and histological manifestations of PD. 
 List risk factor associated with the development of PD. 
 List major therapeutic approaches. 
 List major deficiencies in the treatment of PD. 
 Name therapeutic approaches currently in development to treat PD. 
 
4/17/14 – Traumatic Brain Injury Medicine: A Brief Overview with an Emphasis on Pharmacological Management 
 Identify the basic nomenclature used in Brain Injury Medicine. 
 Recognize the pathophysiology of the injury, especially mild traumatic brain injury. 
 Describe the common potential consequences of a brain injury. 
 Identify pharmacological agents used to improve outcomes in brain injury survivors. 
 
4/24/14 – Medication Challenges for Brain Injury Patients 
 State three common medication challenges for persons living with a brain injury. 
 Identify two or three warning-signs or subtle clues that suggest a possible medication challenge/miscommunication exists 
for brain injury patients. 
 Describe two recommendations you can make to a person living with a brain injury if you recognize warning signs or 
subtle clues suggesting a medication challenge/miscommunication. 
 
5/1/14 – Oxidative Stress and its Role in Underlying Ischemic-Reperfusion-Induced Delayed Neuronal Death 
 Distinguish between the different types of stroke pathologies. 
 Describe how glutamatergic receptors, such as the AMPA receptor, contribute to delayed neuronal death. 
 Describe how subjecting neuronal cells to ischemic-reperfusion can lead to oxidative stress. 
 Describe how activation of oxidative stress signaling cascade can lead to synaptic plasticity and subsequent delayed 
neuronal death. 
 
5/8/14 – The Basic Neurological Exam:  Why We Do What We Do? 
 Differentiate the basic difference between upper and lower motor neuron lesions. 
 Describe the basic physiology behind reflexes and their moderation. 
 Describe the fundaments of a basic assessment of the cranial nerves. 
 Identify the components of a basic assessment of peripheral strength, sensation, and reflexes. 
 Describe the components of the basic mini mental status exam or the Montreal Cognitive Assessment. 
 Be able to make a basic assessment of lesion location based on exam. 
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